Rituxan copycat passes first pivotal test for Amgen, Allergan; Ironwood and biotech spinout name new boards
→ Amgen and their partners at Allergan say their pivotal study of a Rituxan knockoff came through with positive PK results for patients with rheumatoid arthritis. They’re also running a separate pivotal for non-Hodgkin’s lymphoma which will go into their regulatory filing for an approval.
→ New boards have been established for Ironwood and its biotech spinout Cyclerion. Industry vet Julie McHugh will chair the Ironwood board while Cyclerion named Marsha Fanucci — an ex-Genzyme/Millennium exec — to the head of their new board.
→ AIT Therapeutics has licensed commercial rights for its cylinder free nitric oxide generator and phasic-flow delivery system in the US and China to Circassia Pharmaceuticals. It’s a $32.5 million deal.